Giorgio Valabrega

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

Mansoor Raza Mirza, Dana M. Chase, Brian M. Slomovitz et al. · New England Journal of Medicine · 2023 · 800 citations · Full text

Medicine, Oncology, Pharmacology +17

Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy

Eleonora Ghisoni, Alexandre Wicky, Hasna Bouchaab et al. · European Journal of Cancer · 2021 · 186 citations · Full text

Life Sciences, Immunology, Oncology +16

Moderate Immunohistochemical Expression of HER-2 (2+) Without <i>HER-2</i> Gene Amplification Is a Negative Prognostic Factor in Early Breast Cancer

Valentina Rossi, Ivana Sarotto, Furio Maggiorotto et al. · The Oncologist · 2012 · 132 citations · Full text

Medicine, Oncology, Breast Oncology +15

TGFα expression impairs Trastuzumab-induced HER2 downregulation

Giorgio Valabrega, Filippo Montemurro, Ivana Sarotto et al. · Oncogene · 2005 · 129 citations

Life Sciences, Molecular Biology, Oncology +13

Outcome of Patients with HER2-Positive Advanced Breast Cancer Progressing During Trastuzumab-Based Therapy

Filippo Montemurro, Michela Donadio, Matteo Clavarezza et al. · The Oncologist · 2006 · 128 citations · Full text

Medicine, Oncology, Pharmacology +16